News
AKESF
17.05
NaN%
--
KeyBanc Reaffirms Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 5d ago
Akeso, Inc. (9926) Receives a Buy from Guotai Haitong
TipRanks · 04/04 14:55
CICC Remains a Buy on Akeso, Inc. (9926)
TipRanks · 04/04 05:57
Akeso, Inc. (9926) Receives a Buy from BOCOM International Holdings Company
TipRanks · 04/01 06:26
Bank of China Reaffirms Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 04/01 06:25
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
TipRanks · 03/30 14:15
Biotech Alert: Searches spiking for these stocks today
TipRanks · 03/27 15:36
Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026
TipRanks · 03/27 12:21
UBS Sticks to Its Buy Rating for Akeso, Inc. (9926)
TipRanks · 03/27 10:55
Akeso Boosts Revenue and R&D While Trimming Adjusted EBITDA Loss in 2025
TipRanks · 03/26 14:43
Akeso, Inc. (9926) Receives a Hold from Bernstein
TipRanks · 03/18 12:18
Akeso Schedules Board Meeting to Approve 2025 Annual Results
TipRanks · 03/16 09:17
ClearBridge International Value Strategy adds RHHBY and MKGAF; exits GRRMF, AKESF, and HKMPF
Seeking Alpha · 02/19 17:35
Bernstein Sticks to Their Hold Rating for Akeso, Inc. (9926)
TipRanks · 02/09 16:35
Akeso Grants JumpCan Exclusive Mainland China Rights to Cholesterol Drug 伊喜寧®
TipRanks · 02/03 11:40
Summit spikes as lead asset undergoes FDA review
Seeking Alpha · 01/29 12:47
Akeso Details Long-Term MAb Contract Manufacturing and Demand Assumptions
TipRanks · 01/26 10:39
Akeso announces NMPA acceptance of second NDA for gumokimab
TipRanks · 01/19 20:15
Akeso's Cadonilimab Outperforms PD-1 Inhibitors In Gastric Cancer; Stock Up
NASDAQ · 01/14 11:17
Akeso Secures NMPA Label Update For Ivonescimab With Dual Survival Benefits In NSCLC
NASDAQ · 01/07 03:28
More
Webull provides a variety of real-time AKESF stock news. You can receive the latest news about Akeso through multiple platforms. This information may help you make smarter investment decisions.
About AKESF
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.